Rubius Therapeutics to Participate in Guggenheim Healthcare Talks | 2021 Oncology Days

Rhea-AI Summary

Rubius Therapeutics, a clinical-stage biopharmaceutical company, announced on February 3, 2021, that its CEO, Pablo J. Cagnoni, M.D., and the executive management team will participate in a fireside chat at the Guggenheim Healthcare Talks | 2021 Oncology Days. This event is scheduled for February 11, 2021, at 2:30 p.m. EST. A live audio webcast will be available on the company’s website, with an archived replay accessible for 90 days. Rubius is focused on developing Red Cell Therapeutics™ for cancer and autoimmune diseases, leveraging its proprietary RED PLATFORM®.

CAMBRIDGE, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™, today announced that Pablo J. Cagnoni, M.D., president and chief executive officer, and the executive management team will participate in a fireside chat at the Guggenheim Healthcare Talks | 2021 Oncology Days on February 11, 2021, at 2:30 p.m. EST.

A live audio webcast will be available within the Investors & Media section of the Rubius Therapeutics website. An archived replay will be accessible for 90 days following the event.

About Rubius Therapeutics

Rubius Therapeutics is a clinical-stage biopharmaceutical company developing a new class of medicines called Red Cell Therapeutics™. The Company’s proprietary RED PLATFORM® was designed to genetically engineer and culture Red Cell Therapeutics™ that are selective, potent and off-the-shelf allogeneic cellular therapies for the potential treatment of several diseases across multiple therapeutic areas. Rubius’ initial focus is to advance RCT™ product candidates for the treatment of cancer and autoimmune diseases by leveraging two distinct therapeutic modalities — potent cell-cell interaction and tolerance induction. Rubius Therapeutics was recently named among the Top Places to Work in Massachusetts by the Boston Globe, and its manufacturing site was recently named 2020 Top 5 Best Places to Work in Rhode Island among medium-sized companies by Providence Business News. For more information, visit www.rubiustx.com, follow us on Twitter or LinkedIn or like us on Facebook.

Contacts:

Investors
Elhan Webb, CFA, VP Investor Relations
elhan.webb@rubiustx.com

Media
Marissa Hanify, Director, Corporate Communications
Marissa.hanify@rubiustx.com

Dan Budwick, 1AB
+1 (973) 271-6085
dan@1abmedia.com

FAQ

What is Rubius Therapeutics doing at the Guggenheim Healthcare Talks 2021?

Rubius Therapeutics will participate in a fireside chat on February 11, 2021, discussing its developments in cellular medicines.

Who will represent Rubius Therapeutics at the 2021 Oncology Days?

Pablo J. Cagnoni, M.D., the CEO, along with the executive management team, will represent Rubius Therapeutics.

When is the fireside chat at the Guggenheim Healthcare Talks 2021?

The fireside chat is scheduled for February 11, 2021, at 2:30 p.m. EST.

How can I access the live webcast of the Rubius Therapeutics event?

A live audio webcast of the event will be available in the Investors & Media section of Rubius Therapeutics' website.

What are Red Cell Therapeutics by Rubius Therapeutics?

Red Cell Therapeutics are a new class of cellular medicines developed by Rubius Therapeutics for the treatment of cancer and autoimmune diseases.